PMID- 20693130
OWN - NLM
STAT- MEDLINE
DCOM- 20101222
LR  - 20181201
IS  - 1308-0032 (Electronic)
IS  - 1302-8723 (Linking)
VI  - 10
IP  - 4
DP  - 2010 Aug
TI  - Comparison of intracoronary versus intravenous administration of tirofiban in 
      primary percutaneous coronary intervention.
PG  - 340-5
LID - 10.5152/akd.2010.093 [doi]
AB  - OBJECTIVE: The purpose of this study was to compare the intravenous bolus dose of 
      tirofiban with intracoronary bolus dose in primary percutaneous coronary 
      intervention (PCI) with regard to in hospital and six months clinical outcomes 
      and peak cardiac enzyme levels. METHODS: We retrospectively examined 84 ST 
      elevation myocardial infarction (STEMI) patients who underwent primary PCI from 
      March 2006 to February 2007. All patients received the systemic bolus dose of 
      tirofiban 10 mcg/kg either via intracoronary (IC) or intravenous (IV) route, 
      followed by a 36 hours of IV infusion at 0.15 mcg/kg/min. Thirty six patients in 
      IC group were compared with 48 patients in IV group in terms of peak cardiac 
      enzyme levels, in-hospital and six months major adverse cardiac events (MACE) 
      rates (death, myocardial infarction and repeat revascularization). Fisher's exact 
      test, Yates Chi-square, unpaired Student's t-test and Mann-Whitney U test were 
      used for statistical analysis. RESULTS: There was no difference in cardiovascular 
      risk profile or cardiac history between two groups. At six months the incidence 
      of MACE was 6.25% in IV group and 11.1% in IC group (p=0.45). Peak cardiac 
      phosphokinase (CPK) levels between IV and IC groups were also statistically non 
      significant (2657+/-2181 U/L in IV group and 2529+/-1929 U/L in IC group) 
      (p=0.92). CONCLUSION: Intracoronary bolus application of tirofiban was not 
      associated with reduction in MACE rates compared to intravenous administration in 
      patients with STEMI who underwent primary PCI. Future prospective trials with 
      higher bolus doses of IC tirofiban should addressed to clarify this issue.
FAU - Erdim, Refik
AU  - Erdim R
AD  - Department of Cardiology, Florence Nightingale Hospital, Istanbul Bilim 
      University, Istanbul, Turkey. errefik@hotmail.com
FAU - Erciyes, Demet
AU  - Erciyes D
FAU - Gormez, Selcuk
AU  - Gormez S
FAU - Karabay, Kanber Ocal
AU  - Karabay KO
FAU - Catakoglu, Alp Burak
AU  - Catakoglu AB
FAU - Aytekin, Vedat
AU  - Aytekin V
FAU - Demiroglu, Cemsid
AU  - Demiroglu C
FAU - Gulbaran, Murat
AU  - Gulbaran M
LA  - eng
PT  - Journal Article
PL  - Turkey
TA  - Anadolu Kardiyol Derg
JT  - Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
JID - 101095069
RN  - 0 (Fibrinolytic Agents)
RN  - 42HK56048U (Tyrosine)
RN  - EC 2.7.3.2 (Creatine Kinase)
RN  - GGX234SI5H (Tirofiban)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angioplasty, Balloon, Coronary/methods
MH  - Creatine Kinase/blood
MH  - Fibrinolytic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Follow-Up Studies
MH  - Humans
MH  - Injections, Intravenous
MH  - Middle Aged
MH  - Myocardial Infarction/blood/physiopathology/*therapy
MH  - Retrospective Studies
MH  - Stroke Volume
MH  - Tirofiban
MH  - Treatment Outcome
MH  - Tyrosine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
EDAT- 2010/08/10 06:00
MHDA- 2010/12/24 06:00
CRDT- 2010/08/10 06:00
PHST- 2010/08/10 06:00 [entrez]
PHST- 2010/08/10 06:00 [pubmed]
PHST- 2010/12/24 06:00 [medline]
AID - 10.5152/akd.2010.093 [doi]
PST - ppublish
SO  - Anadolu Kardiyol Derg. 2010 Aug;10(4):340-5. doi: 10.5152/akd.2010.093.